Produced in the fall of 2023, this film introduces Amplio Pharma and its 3 female founders,
as well as our ambitions for NovoBioJect:
But the seed for Amplio Pharma was planted 20+ years ago when we all worked at Astra Zeneca in Lund, Sweden.
​
The combination of our different expertises - Charlott in pharmacology, Karin in immunology and Marguerite in pharmacy - laid the foundation for us to develop a modified retention technology that we apply in our NovoBioJect. Here we see a clear opportunity to make a real difference in the lives of patients: amplification of the Gold Standard.
​
We filed a patent disclosing NovoBioJect in May 2017 and founded the company Amplio Pharma after we received a positive opinion back from the EPO. The patent was awarded by the EPO in August 2021 and the USPO in January 2024.
Karin von Wachenfeldt (centre): "I want the patients to feel better so they can fully take back their lives."
Charlott Brunmark (left): "The great thing with NovoBioJect is the modified retention. It will amplify the treatment effect of methotrexate"
Marguerite Mensonides (right): "With this novel use of novobiocin we have a small molecule that is known to be safe in humans. How lucky to have nature provide us with this PK enhancer for methotrexate!"